MRSN PE Ratio & Valuation,Is MRSN Overvalued

MRSN Relative Valuation

MRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRSN is overvalued; if below, it's undervalued.

Historical Valuation

Mersana Therapeutics Inc (MRSN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.42 is considered Overvalued compared with the five-year average of -3.38. The fair price of Mersana Therapeutics Inc (MRSN) is between 6.15 to 17.88 according to relative valuation methord. Compared to the current price of 28.60 USD , Mersana Therapeutics Inc is Overvalued By 59.94%.

Relative Value

Fair Zone

6.15-17.88

Current Price：28.60

59.94%

Overvalued

-2.09

0.00

EV/EBITDA

Mersana Therapeutics Inc. (MRSN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.92. The thresholds are as follows: Strongly Undervalued below -6.71, Undervalued between -6.71 and -4.31, Fairly Valued between 0.47 and -4.31, Overvalued between 0.47 and 2.86, and Strongly Overvalued above 2.86. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.93

EV/EBIT

Mersana Therapeutics Inc. (MRSN) has a current EV/EBIT of -0.93. The 5-year average EV/EBIT is -1.83. The thresholds are as follows: Strongly Undervalued below -6.60, Undervalued between -6.60 and -4.21, Fairly Valued between 0.55 and -4.21, Overvalued between 0.55 and 2.94, and Strongly Overvalued above 2.94. The current Forward EV/EBIT of -0.93 falls within the Historic Trend Line -Fairly Valued range.

9.42

Mersana Therapeutics Inc. (MRSN) has a current PS of 9.42. The 5-year average PS is 2167.86. The thresholds are as follows: Strongly Undervalued below -15537.07, Undervalued between -15537.07 and -6684.61, Fairly Valued between 11020.33 and -6684.61, Overvalued between 11020.33 and 19872.79, and Strongly Overvalued above 19872.79. The current Forward PS of 9.42 falls within the Historic Trend Line -Fairly Valued range.

-2.02

P/OCF

Mersana Therapeutics Inc. (MRSN) has a current P/OCF of -2.02. The 5-year average P/OCF is -4.11. The thresholds are as follows: Strongly Undervalued below -10.57, Undervalued between -10.57 and -7.34, Fairly Valued between -0.87 and -7.34, Overvalued between -0.87 and 2.36, and Strongly Overvalued above 2.36. The current Forward P/OCF of -2.02 falls within the Historic Trend Line -Fairly Valued range.

-1.96

P/FCF

Mersana Therapeutics Inc. (MRSN) has a current P/FCF of -1.96. The 5-year average P/FCF is -4.25. The thresholds are as follows: Strongly Undervalued below -10.58, Undervalued between -10.58 and -7.42, Fairly Valued between -1.09 and -7.42, Overvalued between -1.09 and 2.07, and Strongly Overvalued above 2.07. The current Forward P/FCF of -1.96 falls within the Historic Trend Line -Fairly Valued range.

Mersana Therapeutics Inc (MRSN) has a current Price-to-Book (P/B) ratio of -2.38. Compared to its 3-year average P/B ratio of 23.00 , the current P/B ratio is approximately -110.35% higher. Relative to its 5-year average P/B ratio of 15.50, the current P/B ratio is about -115.36% higher. Mersana Therapeutics Inc (MRSN) has a Forward Free Cash Flow (FCF) yield of approximately -52.48%. Compared to its 3-year average FCF yield of -83.15%, the current FCF yield is approximately -36.88% lower. Relative to its 5-year average FCF yield of -56.87% , the current FCF yield is about -7.73% lower.

-2.40

P/B

Median3y

23.00

Median5y

15.50

-52.48

FCF Yield

Median3y

-83.15

Median5y

-56.87

Competitors Valuation Multiple

The average P/S ratio for MRSN's competitors is 0.00, providing a benchmark for relative valuation. Mersana Therapeutics Inc Corp (MRSN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -12.61%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MRSN decreased by 20.03% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.73 to -2.03.

The secondary factor is the Revenue Growth, contributed -12.61%to the performance.

Overall, the performance of MRSN in the past 1 year is driven by P/E Change. Which is more unsustainable.

-12.61%

12.60M → 11.01M

Revenue Growth

-24.93%

-91.29 → -68.53

Margin Expansion

17.51%

-1.73 → -2.03

P/E Change

-20.03%

35.75 → 28.59

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Mersana Therapeutics Inc (MRSN) currently overvalued or undervalued?

What is Mersana Therapeutics Inc (MRSN) fair value?

MRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mersana Therapeutics Inc (MRSN) is between 6.15 to 17.88 according to relative valuation methord.

How does MRSN's valuation metrics compare to the industry average?

What is the current P/B ratio for Mersana Therapeutics Inc (MRSN) as of Dec 16 2025?

As of Dec 16 2025, Mersana Therapeutics Inc (MRSN) has a P/B ratio of -2.38. This indicates that the market values MRSN at -2.38 times its book value.

What is the current FCF Yield for Mersana Therapeutics Inc (MRSN) as of Dec 16 2025?

As of Dec 16 2025, Mersana Therapeutics Inc (MRSN) has a FCF Yield of -52.48%. This means that for every dollar of Mersana Therapeutics Inc’s market capitalization, the company generates -52.48 cents in free cash flow.

What is the current Forward P/E ratio for Mersana Therapeutics Inc (MRSN) as of Dec 16 2025?

As of Dec 16 2025, Mersana Therapeutics Inc (MRSN) has a Forward P/E ratio of -2.08. This means the market is willing to pay $-2.08 for every dollar of Mersana Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Mersana Therapeutics Inc (MRSN) as of Dec 16 2025?

As of Dec 16 2025, Mersana Therapeutics Inc (MRSN) has a Forward P/S ratio of 9.42. This means the market is valuing MRSN at $9.42 for every dollar of expected revenue over the next 12 months.

MRSN Valuation